Change is the hallmark of health care and health information technology (healthIT). This year promises to be another with tectonic shifts. On one hand, healthIT will continue to respond to evolving changes in the health care ecosystem by building on what has been in the pipeline. On the other, several new entrants into that ecosystem will significantly affect health care and healthIT going forward. With that in mind, here are the top 10 trends we see ahead in 2015 for healthIT.
EHRs: Will only the strong survive as this market consolidates? In 2015, we could see increased consolidation in the electronic health record (EHR) market, mostly involving integrated delivery networks (IDNs). The emergence of value-based reimbursement and other market forces have fostered a migration of physicians and small groups into large group practices. The gamut of individual EHR systems represented by acquired practices will be abandoned or gradually swapped out as these merged entities focus on an enterprise solution. Not surprisingly, enterprise systems favor large, well-established vendors.
Nonetheless, opportunities do exist for small- and medium-sized firms. Those focused on meeting specialists unmet needs will have an advantage. EHRs offering cloud-based platforms will continue to increase market share.
Population health: Why well finally see it pop. Payers, policy makers and IDNs will have population health on their minds in 2015 more than ever before. Why? Because it makes sense from a business perspective and promises a fairly quick return on investment (ROI). Part of meaningful use (MU) and the federal strategic plan for healthIT for 2015 to 2020, population health represents a tectonic shift away from treating episodes of care for individual patients to managing the health of specific populations, such as the chronically ill or members of IDNs.
Part of this is driven by a renewed focus on value-based reimbursement, with the recent announcement that Medicare will move away from fee-for-service medicine and transition toward payment through such alternative reimbursement models as bundled payments, patient-centered medical homes (PCMHs) and accountable care organizations (ACOs). This new way of doing business based on value-based reimbursement will require changes to healthIT infrastructures and EHRs to capture clinical, administrative, cost and outcomes data. EHRs and health information exchanges (HIEs) will be needed to gather and report data, both internally and externally, to payers such as Medicare.
Another driver is the business case for population health, represented by ROI. According to a survey by KPMG, half of health care organizations could recoup their population health investment within a short four-year window, many within the first 1 to 2 years.
Clinical decision support: Docs will learn to love it. This year will mark a turning point in the provider community, which will come to perceive clinical decision support (CDS) as a value-add and must-have rather than simply an annoyance. MU stage 2 includes several CDS requirements, but some providers consider these to be too much and too heavy handed. Others especially early adopters will be rethinking it. Savvy physicians have become comfortable with basic CDS and are now looking to expand beyond the basics to more advanced features.
These physicians, along with IDNs and ACOs, have realized that effective use of CDS means patients receiving the correct tests and preventive services, appropriate medications, and proper treatment, particularly for chronic conditions. This translates to better outcomes, which lead to successful value-based reimbursement. As a result, clinician demand for more and improved CDS will stimulate EHR vendors to respond. They will be adding such CDS tools as documentation templates, diagnostic support, condition-specific order sets, focused patient data reports and summaries and evidence-based guidelines all of which may be deployed on a variety of platforms (e.g., mobile, cloud based or locally installed). Look also for CDS tools to enhance clinicians quality of patient care in PCMHs and ACOs, as well as remote patient monitoring.
Patient engagement: It will lead to innovative market marriages. Engaging patients in their care has been disappointingly slow despite its being part of MU, significant noise coming out of Washington and increased demand by some patients and IDNs. This could be the year patient engagement begins to take off. Under pressure to reduce costs and improve outcomes both within value-based reimbursement systems and outside payers and providers will be looking for patient engagement solutions, particularly those that are technology-based, to drive action and get results.
Moreover, the need for better patient engagement is an opportunity that investors and entrepreneurs will jump on in 2015. This should not be surprising given low interest rates, increased availability of venture capital and growing awareness throughout the business community of the need to cut health care costs while promoting wellness. That should translate into a wider range of wearables, mobile devices and applications to monitor patients and help them meet clinical and lifestyle targets customized to their age, health status, conditions and insurance coverage. Expect to see greater innovation in electronic patient/provider messaging that provides targeted actionable information across various patient populations as well as meaningful feedback.
Data sharing is another area that is ripe for opportunity, particularly regarding ways patients can contribute information to their EHRs and how caregivers can be included. Both entrepreneurs and institutions are looking to leverage technology to educate patients about their care and conditions. Innovative healthIT solutions are needed to reach the elderly and many minorities, who tend to be underserved and have multiple chronic illnesses that are costly to treat.
Electronic health records: Will they be easier to use? Washington is abuzz these days with the perceived need for better healthIT interoperability. We heartily support ongoing work by the industry and federal government for improvements in this area. Take, for example, suggestions in the new draftRoadmap recently issued by the Office of the National Coordinator for Health Information Technology (ONC) and its 2015 Interoperability Standards Advisory(the ). To be sure, these initiatives will drive interoperability, but newly announced payment reforms will be the game changer. (Learn more in our related article in this issue of HIT Perspectives.)
While ONCs interoperability recommendations are being finalized, the industry in 2015 will be building on MU requirements and processes that have already left a core of basic interoperability supported across many EHR vendors. MUs cookie-cutter approach has created usability gaps that vendors will be working to address. Physicians want systems that are straightforward to use, more easily and securely integrated into their work flows, and customized to the unique needs of their specialties. Many will be replacing hastily purchased EHRs because they desire enhanced functionalities, such as specialty-specific work flows. That lesson is underscored in a recent survey by the American Academy of Family Practice, which found that 59% of family physicians who switched EHRs got better functionality the top reason for the change in the first place. Other physicians will be implementing new EHRs because they will be joining IDNs that require use of a particular system. IDNs, ACOs and even large group practices will need expanded data capture, analytics and reporting capabilities.
Biosimilars: They will be blinding us with science. One of the newest trends is the entrance of biosimilar pharmaceuticals into the US market. The Food and Drug Administration is poised to begin approving these drugs, which are similar to, but not identical copies of, the originator biologic and are not generic alternatives. (For a more detailed primer on biosimilars, see our article in the December 2014 issue of HIT Perspectives.) We expect that the trickle of approved biosimilars soon will turn into a flood, creating numerous challenges and opportunities for healthIT in terms of standards and changes to EHRs and dispensing systems. Many of these will be driven by the need to add the manufacturer name and lot number to the drug ecosystem in response to provisions of the Drug Quality and Security Act of 2013. These changes will be needed to track and trace adverse drug events potentially associated with biosimilars and other medications. That is easier said than done as normal industry practices, and the standards used for electronic communication between prescribers and pharmacists, dont typically contain lot number or manufacturer information.
Specialty medications: ePrescribing will be the prescription for success. Specialty medications will continue to be of intense interest by payers and providers as their costs and share of the nations drug spend continue to rise. The rise in biosimilars also will contribute to the focus on specialty meds. As a result, emphasis will be placed on using electronic prescribing (ePrescribing) and prior authorization (PA) to improve management of the prescribing and distribution processes of these medications and reduce the significant overhead costs associated with todays paper/phone/fax processes.
In fact, ePrescribing of specialty medications is already in use today on a limited basis. One barrier to wider use of ePrescribing for specialty medications is that the data transmitted do not contain vital information such as height, weight and PA approvals needed by the specialty pharmacy. This means the pharmacy must request additional information from the prescriber and revert back to paper- and fax-based processes. The industry is aware of these gaps and will continue to work on filling them. Examples include the wider integration of electronic prior authorization (ePA) into EHRs and modification of the prescription transaction standard to accommodate this information. We will also see more robust integration of pharmacy and medical benefits, thus allowing plans to better track the usage of specialty drugs across beneficiaries. This will necessitate major changes in ePrescribing, standards and payer and pharmacy systems.
EPCS: Adoption will be getting a shot in the arm. Electronic prescribing of controlled substances (EPCS) will continue to gain traction in 2015. Part of this is because EPCS is the final frontier of ePrescribing and it is natural that market forces will try to fill the void. Pharmacies are ready for EPCS. So are EHR vendors, which are increasingly bringing EPCS-compliant products to market now that demand has been demonstrated. In addition, the process for accrediting EPCS-compliant products will be streamlined now that the Electronic Healthcare Network Accreditation Commission (EHNAC) is exclusively handling certification. This should result in more EPCS-compliant products hitting the market sooner and will stimulate adoption by providers. The move toward interoperability and value-based care by public and private payers also should stimulate EPCS adoption in 2015. (Read more in this issue of HIT Perspectives.)
Another major driver for EPCS is the war against substance abuse being led by the federal and state governments. One example is the I-STOP Program in New York, which requires ePrescribing of all medications in March 2015 and the consultation by most prescribers of the states Prescription Drug Monitoring Program (PDMP) Registry when writing prescriptions for Schedule II, III, and IV controlled substances. The PDMP Registry provides practitioners with direct, secure access to view dispensed controlled substance prescription histories for their patients. This information will allow practitioners to better evaluate their patients’ treatment with controlled substances and determine whether there may be abuse or nonmedical use. Many states are considering following New Yorks lead, which would not be that difficult since all states have a monitoring program that is authorized or already up and running. A challenge to more widespread adoption, however, is that while providers are adopting EPCS-compliant ePrescribing systems, PDMP data are not yet integrated into the EHR. This represents an opportunity for EHR vendors to fill a market gap with a feature that will yield significant patient safety benefits.
Electronic prior authorization: Health care will just say yes. Vendors in 2015 will increase their implementations of ePA. Despite availability of the standard, its integration into EHRs has been slow. That should change as demand for ePA continues to grow. Some will be due to the entry of biosimilars entering the market, coupled with the increasing demand for specialty medications spurred by the continued rise of chronic diseases. All of these will require PA, eventually creating a tipping point for ePA away from the traditional paper/phone/fax PA methods. In addition, look for payers renewed interest in medical electronic preauthorization. This shift in payer mind-set is fairly easy to understand. Payers are beginning to see the success in ePA for medications now that the standard has become more widely adopted. Paper/phone/fax PA processes for medical procedures, lab tests and devices have been a long-standing and expensive pain point for both payers and providers, and the success in ePA may point to relief for that.
Real-world evidence: Data and methods will be making it real. Wider use of real-world evidence (RWE) will be a major transformational trend in 2015. Expect to see payers, regulators, pharmaceutical companies and others increasingly look at RWE as a new way to assess patient outcomes and create value. Analyses of large sets of anonymized patient-level data, or real-world data (RWD), can yield an assessment of the true effectiveness, risks, safety and cost benefits of a drug, procedure or device. As a result, RWE provides an unprecedented window into how a particular product is used by whom, under what circumstances and yielding what outcomes. Drug manufacturers are now using large data sets and sophisticated analytics to see how their existing drugs actually perform in the real world. This increases their understanding of how drugs actually perform on top of the knowledge gained from the narrow confines and small populations of the gold standard of randomized, controlled clinical trials. RWE will also become increasingly important to payers, providers and regulators. Using RWE, they can have an accurate and advance assessment of the risks and benefits of treatments and actual health outcomes in large patient populations. RWE further can be translated into action-oriented messaging for patients and health care providers at the point of care. Additionally, RWE creates opportunities for healthIT infrastructure vendors to provide the RWD needed for the analyses. Vendors can create value for payers and regulators by collecting and aggregating clinical data from EHRs, as well as by linking claims and registry data.